Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2501-2520 of 3,900 trials

Metycor Study for Autonomous Cortisol Secretion

We are testing a new treatment to see if it improves blood pressure, glucose levels, and overall health in patients with autonomous cortisol secretion. The study also looks at effects on weight, bone health, and quality of life.

Mild Autonomous Cortisol Secretion6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Diabetes and Bone Health: Alendronate Study

We are investigating how the medication Alendronate impacts bone and blood sugar markers in individuals with type 1 and type 2 diabetes. This study aims to compare the effects between the two types of diabetes and different assessment methods.

Diabetes and Bone Health IssuesMonitoring phase (IV)Standard MedicinesDiabetologyEndocrinologyRheumatology

Chronic Lymphocytic Leukemia: Mosunetuzumab and Pirtobrutinib Combination

We are studying the safety and effectiveness of combining two medications for patients with relapsed or refractory chronic lymphocytic leukemia. This research aims to understand how well the body responds to this treatment.

Relapsed or Refractory Chronic Lymphocytic LeukemiaSafety phase (I)HematologyOncology

Yellow Fever Vaccination: Comparing Injection Methods

We are studying how different ways of giving the yellow fever vaccine affect the immune response in participants. This trial aims to find out which method may provide better protection and safety.

Yellow Fever3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

ANCA-Associated Vasculitis: Prednisone Treatment Study

We are investigating whether continuing low-dose prednisone helps maintain remission in patients with ANCA-associated vasculitis compared to stopping it after one month. This study will also look at potential side effects and relapse rates over time.

Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesRheumatology

Advanced Melanoma: Enfortumab Vedotin with Pembrolizumab

We are studying a combination of two treatments for patients with advanced melanoma who have been previously treated. The goal is to see if this combination is effective and safe for improving patient outcomes.

Metastatic MelanomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Solid Tumors: Long-Term Safety of Brigimadlin

We are studying the long-term effects of brigimadlin in people with solid tumors who have previously taken this medication. The goal is to understand how well they tolerate it and any side effects that may occur.

Solid TumoursEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

HER2+ Metastatic Colorectal Cancer: Tucatinib Combination Study

We are investigating whether a new treatment combining tucatinib, trastuzumab, and mFOLFOX6 can improve outcomes for patients with HER2+ metastatic colorectal cancer compared to standard care.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Clear Cell Renal Cell Carcinoma: PET Scan Comparison

We are comparing two different PET scans to see which one detects tumors better in patients with clear cell renal cell carcinoma. This study may help improve diagnosis for those suspected of having this type of cancer.

Metastatic Renal Cell Carcinoma≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Systemic Lupus Erythematosus: GSK4527363 Study

We are investigating a new treatment for systemic lupus erythematosus in healthy individuals and those with the condition. The study includes participants from Chinese and Japanese backgrounds to see how the treatment works across different groups.

Systemic Lupus Erythematosus1-2 yearsSafety phase (I)Rheumatology

Dent 2 Disease: Alpelisib Study

We are testing the medication alpelisib in patients with Dent 2 disease to see if it improves kidney function and is safe to use. This study will help us understand its potential benefits for kidney health.

Dent's DiseaseEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrologyUrology

Navepegritide for Growth in Adolescents with Achondroplasia

We are studying whether navepegritide can help improve growth in adolescents aged 12 to under 18 with achondroplasia. This trial will help us understand its effectiveness and safety.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Advanced Solid Tumors: BGB-B3227 and Tislelizumab

We are testing a new treatment combining BGB-B3227 with Tislelizumab for patients with advanced or metastatic solid tumors. This study aims to understand how effective this combination may be in treating their condition.

Malignant Mast Cell Tumors>2 yearsSafety phase (I)Oncology

EBV Infection: Testing 2LEBV® and 2LXFS® for Fatigue

We are studying whether two new treatments can help reduce fatigue in patients with an EBV infection compared to a placebo. The trial also looks at other symptoms and safety.

Epstein-Barr Virus Infection>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesInfectious Diseases

Advanced Solid Tumors: Targeted Therapy Study

We are testing new targeted treatments for patients with advanced solid tumors to see how well they work for specific tumor types. This study aims to enhance personalized medicine in cancer treatment.

Malignant Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Spinal Muscular Atrophy: Nusinersen via ThecaFlex DRx System

We are studying how the body processes nusinersen when given through the ThecaFlex DRx system in adults and children with spinal muscular atrophy. This research aims to compare it to the standard delivery method.

Spinal Muscular Atrophy1-2 yearsSafety phase (I)No PlaceboStandard MedicinesHematologyInternal MedicineNeurology

Cholangiocarcinoma: Ivosidenib with Durvalumab and Gemcitabine/Cisplatin

We are studying a new treatment combination for patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The goal is to evaluate its safety and early effectiveness as a first-line therapy.

Cholangiocarcinoma>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Severe Functional Disorders: Duloxetine and Patient Education

We are studying the effects of patient education and duloxetine on individuals with severe functional disorders. This research aims to explore how these factors may influence symptoms and inflammation.

Functional Somatic Disorder3-6 monthsMonitoring phase (IV)Investigational MedicinesInternal MedicineNeurologyPsychiatry

Advanced NSCLC: NVL-655 Treatment Study

We are testing a new medication, NVL-655, for patients with advanced ALK-positive non-small cell lung cancer and other solid tumors. The study aims to evaluate its safety and effectiveness, especially for those with resistance to current treatments.

Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK MutationSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Esophageal Cancer: Ifinatamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for people with untreated advanced esophageal cancer. The goal is to see if it is safe and effective compared to standard options.

Esophageal Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesOncology